KROS vs XLV
Keros Therapeutics Inc (KROS) versus Health Care Select Sector SPDR® Fund (XLV) — a side-by-side from cached financials, not a winner call.
Keros Therapeutics Inc (KROS) is a biotechnology company listed on US.
Health Care Select Sector SPDR® Fund (XLV) common stock listed on US.
Latest reported KROS revenue for 2026-06-30 was $32.0K. Net income was -$52.4M. Revenue was up 0.0% from 2026-03-31 to 2026-06-30. KROS currently screens at market cap $208.8M.
XLV does not have a complete income-statement cache yet.
KROS currently screens at market cap $208.8M. XLV currently screens at market cap $0.
Not investment advice. Open the KROS and XLV stock pages for the full models.
Not investment advice.